Shanghai, China The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
Among the most popular fund investment industries, there are Software, Medical. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Ultivue, TenNor Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.
The fund is constantly included in less than 2 deals per year. This Frontline BioVentures works on 4 percentage points more the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. The increased amount of exits for fund were in 2018.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the Frontline BioVentures, startups are often financed by F-Prime Capital, Lilly Asia Ventures, Hansjoerg Wyss. The meaningful sponsors for the fund in investment in the same round are Yonghua Capital, WuXi Healthcare Ventures, Temasek Holdings. In the next rounds fund is usually obtained by Temasek Holdings, Taikang Life Insurance, Legend Capital.
The current fund was established by Lianyong Chen. We also calculated 1 valuable employee in our database.
Related Funds
| Fund Name | Location |
| ADV | England, London, United Kingdom |
| AlphaBlock Capital | - |
| Ampal-American Israel | Herzliya, Israel, Tel Aviv |
| Business Angels Switzerland (BAS) | Switzerland, Zürich, Zurich |
| Cocos Blockchain Expedition | Beijing, Beijing, China |
| DeltaPoint Capital Management | New York, Rochester, United States |
| Dubai Future Accelerators | Dubai, United Arab Emirates |
| eonCapital | Centennial, Colorado, United States |
| GHO Capital | England, London, United Kingdom |
| Great Pacific Securities | - |
| Homebrew | California, San Francisco, United States |
| Inlign Wealth | - |
| InOne Media | China, Guangdong, Panyu |
| Leo Partners Investment | Seoul, Seoul-t'ukpyolsi, South Korea |
| Natural Gas Partners | Irving, Texas, United States |
| Panasonic | Japan, Kadoma, Osaka Prefecture |
| Primecap Management | California, Pasadena, United States |
| Zheke Huifu Chuang Tou | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $170M | 09 Sep 2019 | Dongcheng District, Beijing, China | |||
Ultivue | $20M | 23 Jan 2018 | Cambridge, Massachusetts, United States | ||
Yidebang | $9M | 09 Nov 2017 | Beijing | ||
TenNor Therapeutics | $25M | 19 Sep 2016 | New Jersey, United States | ||
Hua Medicine | $50M | 21 Apr 2016 | Shanghai, China | ||
Coherent Biopharma | $8M | 01 Feb 2016 | Suzhou, Jiangsu, China | ||
xInnovent Biologics | $115M | 22 Jan 2015 | Gusu District, Jiangsu, China | ||
Hua Medicine | $25M | 08 Jan 2015 | China, Shanghai |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $170M | 09 Sep 2019 | Dongcheng District, Beijing, China | |||
Ultivue | $20M | 23 Jan 2018 | Cambridge, Massachusetts, United States | ||
Yidebang | $9M | 09 Nov 2017 | Beijing | ||
TenNor Therapeutics | $25M | 19 Sep 2016 | New Jersey, United States | ||
Hua Medicine | $50M | 21 Apr 2016 | Shanghai, China | ||
Coherent Biopharma | $8M | 01 Feb 2016 | Suzhou, Jiangsu, China | ||
xInnovent Biologics | $115M | 22 Jan 2015 | Gusu District, Jiangsu, China | ||
Hua Medicine | $25M | 08 Jan 2015 | China, Shanghai |
